Nebenwirkungen · Bimzelx
Bimzelx 160 mg solution for injection in pre-filled syringe Bimzelx 320 mg solution for injection in pre-filled syringe Bimzelx 160 mg solution for injection in pre-filled pen Bimzelx 320 mg solution for injection in pre-filled pen · Abschnitt 4.8 · PDF-Seite 8
HOS-146299 · Präparat HOS-099486
Approximately 44% of patients with AS treated with bimekizumab up to 52 weeks at the recommended dosing regimen (160 mg every 4 weeks) had anti-drug antibodies. Of the patients with anti-drug antibodies, approximately 44% (20% of all patients treated with bimekizumab) had antibodies that were classified as neutralising.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-05-08T16:53:00Z · SHA-256 caa921571142f6a5edc79dd18f7931333acd6330de2f856395887db3b9d20aca · Passage 6b4e9baaf48976abd6f1189103ff83c906e587966e4453e3a02bbde58bc4610f · Zeichen 7325–7646 im Abschnitt